EFNB2 and small cell lung carcinoma: Given the potential clinical promise for topoisomerase I inhibition in the context of SCLC and the observation that EphB4 knockdown in combination with topoisomerase I inhibition demonstrates additive reduction of cell viability, we examined the activity of topoisomerase I in response to stimulation of EphB4/ephrin-B2 signaling.